Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
OraSure Technologies is empowering the global community to improve health and well...
OraSure Technologies is empowering the global c...
Akcea Therapeutics is a development and commercialization company focused on helpi...
Akcea Therapeutics is a development and commerc...
Premier operates one of the nationâs largest performance improvement alliances o...
Premier operates one of the nationâs largest ...
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company fo...
Amarin Corporation plc. is a rapidly growing, i...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
We are a biopharmaceutical company focused on developing our pipeline featuring sp...
We are a biopharmaceutical company focused on d...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...
Karyopharm Therapeutics is an innovation-driven...
Join the National Investor Network and get the latest information with your interests in mind.